Nonsense mutations introduce a premature termination codon (PTC) and are the underlying cause of multiple rare genetic diseases and cancers. Although certain aminoglycosides bind to eukaryotic ribosomes enabling incorporation of an amino acid at the PTC and formation of full-length protein, they are inefficient and toxic at therapeutic doses. Library screening in assays that measure readthrough at a PTC in the TP53 gene in human HDQ-P1 cells identified six novel 2-aminothiazole-4-carboxamide derivatives that potentiate the PTC readthrough (PTCR) efficiency of G418 when used in combination. The two most potent compounds incorporated a 4-indazole motif on the 2-aminothiazole nitrogen and a hydrophobic aryl substituent on the carboxamide nitrogen. These compounds are valuable tools to further investigate the therapeutic potential of aminoglycoside-induced PTCR.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6511968PMC
http://dx.doi.org/10.1021/acsmedchemlett.8b00610DOI Listing

Publication Analysis

Top Keywords

premature termination
8
2-aminothiazole-4-carboxamides enhance
4
enhance readthrough
4
readthrough premature
4
termination codons
4
codons aminoglycosides
4
aminoglycosides nonsense
4
nonsense mutations
4
mutations introduce
4
introduce premature
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!